EPISODE · Sep 5, 2025 · 45 MIN
Daniel O'Connell, CEO of Acumen Pharmaceuticals, on Oligomers, Innovation, and Hope in Alzheimer’s
from Power to the Patients · host Brandon Li
With over 25 years of experience building and investing in CNS companies, Daniel shares the story of why he placed a big bet on Acumen — from its origins as a seed-stage idea to today’s phase 2 clinical trial, Altitude AD. He explains the science behind targeting amyloid beta oligomers (rather than plaques), what makes Alzheimer’s research uniquely difficult, and why recent advances in biomarkers, trial design, and patient recruitment give him hope for meaningful progress.
What this episode covers
With over 25 years of experience building and investing in CNS companies, Daniel shares the story of why he placed a big bet on Acumen — from its origins as a seed-stage idea to today’s phase 2 clinical trial, Altitude AD. He explains the science behind targeting amyloid beta oligomers (rather than plaques), what makes Alzheimer’s research uniquely difficult, and why recent advances in biomarkers, trial design, and patient recruitment give him hope for meaningful progress.
NOW PLAYING
Daniel O'Connell, CEO of Acumen Pharmaceuticals, on Oligomers, Innovation, and Hope in Alzheimer’s
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m